Plunkett Research Online: Clinuvel Pharmaceuticals Ltd

CLINUVEL PHARMACEUTICALS LTD (CLVLF:PINX) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Clinuvel distributes a single-product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient’s quality of life. Scenes.....



Clinuvel Pharmaceuticals Ltd
Ticker: CLVLF
Exchange: PINX
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 61 396604900
Fax: 61 396604999
Address: 535 Bourke Street
Level 22
Melbourne, VIC 3000 Australia

Map
Types Of Business
Industry Ranks

Industry NAICS code:

Pharmaceutical Preparation Manufacturing
Contacts Description
Philippe WolgenCEO/Director/Managing Director
Karen AgersborgDirector
See More
Clinuvel distributes a single-product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient’s quality of life. Scenes.....See More See More

Auditor: Grant Thornton Audit Pty Ltd
Legal Advisor:
$USD, In whole numbers,
except marked * or %
202420232022202120202019
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and Affiliates Top Salaries
Other Thoughts Corporate Culture

Apparent Female Officers or Directors: